GlobeNewswire

Corvil Wins Best Time Synchronisation Solution at A-Team Group's RegTech Awards 2018

Dela

Corvil's UTC Traceability solution for MiFID and CAT compliance recognized for its innovation and value in accelerating customer compliance with emerging regulations

DUBLIN, Ireland, May 04, 2018 (GLOBE NEWSWIRE) -- Corvil continues to be recognized as the "gold-standard" for machine-time analytics, achieving the "Best Time Synchronisation Solution" award in the A-Team Group's RegTech Awards 2018, for its Coordinated Universal Time (UTC) Solution for MiFID and CAT Compliance.

Regulatory bodies have turned to time precision and integrity as a critical dependency for  providing transparency, auditability, and accountability for algorithmic business such as digital financial transactions, including electronic trading.   Under MiFID II and incoming Consolidated Audit Trail (CAT) rules, market participants must establish, demonstrate and maintain clock synchronization with a Coordinated Universal Time (UTC) source to a high degree of accuracy.  

Corvil's UTC Traceability solution watches over clock synchronization integrity to assure compliance and reduce regulatory tail risk.   Furthermore, it demonstrates the firm's ability to excel in agile innovation and build cost-effective solutions to extend its business and operational value to help customers respond to evolving regulatory regimes.

"We have long seen precision time-handling as the basis for establishing causality for forensics as well as accurate business transaction analysis, network and application performance management, and cyber-security," said Raymond Russell, Corvil's co-founder and CTO.   "Our core platform's handling of time, short time-scale analysis, and identification of clock synchronization status by message not only provide a key asset for current and future regulatory compliance, but is proving a minimum requirement for effective digital business, cyber surveillance, and AI Ops."

Corvil has a nearly 20-year history of shaping trading and algorithmic business technology through transforming network data into intelligence for execution performance, client intelligence and experience, regulatory compliance and cyber risk surveillance.  The firm's industry-leading precision in nanosecond time-stamping of every reportable event in a transaction's lifecycle goes well beyond current regulatory requirements. 

Providing a solution to likely address future tightening of clock synchronization and timestamping requirements, Corvil Analytics delivers a robust, long-term solution for customers.   This forward-looking capability, Corvil's de facto industry standard solution for trade performance monitoring, as well as automated daily and on-demand reporting for compliance and business teams are among the differentiators that have propelled Corvil's RegTech success.  Today, Corvil proudly counts almost every major stock exchange and global bank as a customer.

"We are pleased to congratulate Corvil on their prestigious RegTech Awards 2018 win," said Laurie McAughtry, Editor at A-Team Group.  "Our readership of senior trading technology executives clearly recognized Corvil's contributions to their operational, business, and compliance solutions in voting Corvil as the leading provider of Best Time Synchronisation Solution."

"We are delighted with the recognition of our UTC Traceability Solution from our peersMiFID II and CAT are significant not only to the world of finance but to the wider business landscape as they represent a new era of digital algorithmic and AI oversight through the lens of machine-time, - where faster and smarter machine technology operates autonomously at nanosecond speed," said David Murray, Chief Marketing and Business Development Officer at Corvil.  "Our expertise in this  new reality of time , puts us in a strong position to address future regulatory rules as well as apply our RegTech capabilities to other algorithmic and AI powered businesses."

Corvil's strong performance in empowering firms with insight into client and trader intelligence, market data quality, order and transaction performance as well as technology performance to optimize execution, continues to garner peer recognition.  In the past 12 months the firm achieved "Best Time-Stamping / Infrastructure Performance Monitoring" at Intelligent Trading Technology Awards 2017; "Best Financial Transaction Security Platform" in 2018 FinTech Breakthrough Awards while Institutional Investor recently named Corvil CEO, Donal Byrne, among world's top 25 Innovators in trading technology.

About Corvil
Corvil is the industry leader for deriving Security, Operational, and Business intelligence from network data. As companies adopt faster and smarter machine technology, it becomes critical to tap into richer and more granular machine data sources to safeguard the transparency, performance and security of critical infrastructure and business applications. The Corvil streaming analytics platform captures, decodes, and learns from network data on the fly, transforming it into machine-time intelligence for network, IT, security and business teams to operate efficiently and securely in this new machine world. Corvil uses an open architecture to integrate the power of its network data analytics with the overall IT ecosystem providing increased automation and greater operational and business value outcomes for its users. The Corvil solution is trusted by leading financial institutions to safeguard their businesses across the globe involving 354 trillion messages with a daily transaction value in excess of $1 trillion.

Learn more about Corvil: Corvil.com | Twitter | LinkedIn

Media Contact
Press Office at Corvil
+353 1 859 1040
pressoffice@corvil.com

A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/b1fcbd60-7b75-44f0-b25d-40b32fb0c975




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Corvil via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum